Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 15 Dec 2023
lowest dose produced the least amount of toxicity and the highest overall response rate.
Read Full NewsFindings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
1.
Datopotamab Deruxtecan Earns New Breast Cancer Indication
2.
Both DNA damage repair deficiency and non-Hodgkin lymphoma are the focus of LP-284.
3.
Clinical Evidence Shows Venetoclax Combo Is Safe and Effective in AML Patients 80 Years of Age and Up.
4.
The pancreatic ductal adenocarcinoma mRNA vaccine holds promise for preventing relapse.
5.
CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma
1.
Engineered Red Blood Cell Therapeutics: Emerging Applications
2.
A New Hope: Exploring Treatment Options for Waldenstrom's Macroglobulinemia
3.
AI Meets the Gut Microbiome: Early Detection of GI Malignancies Redefined
4.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
5.
Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge